For millions of people watching dramatic “before-and-after” videos of weight-loss injections on social media, the dream has looked simple: take the weekly shot, lose the weight, and move on with life. But a major new international study now suggests the reality may be far more complicated — and far more permanent.

Fresh research presented at the European Congress on Obesity 2026 in Istanbul and simultaneously published in The Lancet has found that people who stopped taking tirzepatide, one of the world’s most talked-about anti-obesity injections, rapidly regained much of their lost weight despite continuing lifestyle changes. Scientists say the findings reinforce a growing medical belief that obesity behaves less like a temporary illness and more like a chronic lifelong condition.

The study, led by Dr Deborah Horn of UTHealth Houston and funded by Eli Lilly and Company, tracked 441 adults across 20 sites in the United States over 112 weeks. Participants were living with obesity or overweight-related health complications and were given weekly injections of tirzepatide, a medicine that reduces hunger and improves blood sugar control by copying natural hormones involved in appetite.

At the start, the average participant weighed nearly 114 kilograms, with many also facing dangerous risks linked to obesity, including raised blood pressure, unhealthy cholesterol and metabolic disease. Over the first 60 weeks, many participants lost striking amounts of weight. Clinic teams measured shrinking waistlines, improving blood pressure and better blood sugar readings. For some patients, ordinary tasks such as climbing stairs or walking longer distances reportedly became easier again.

But the real drama began after the weight loss plateaued.

Researchers divided participants into three groups. One continued the maximum tolerated dose of tirzepatide, another reduced the dose to 5 mg, while the third group was switched to a placebo — essentially a dummy treatment. The difference soon became impossible to ignore.

Those who remained on the highest dose were seven times more likely to maintain at least 80% of their weight loss compared with people who stopped treatment. Even participants shifted to the smaller 5 mg maintenance dose were four times more likely to keep the weight off.

The placebo group, however, experienced what obesity specialists often describe as the body’s “rubber-band effect”. Once the medicine stopped, the body appeared to push aggressively toward regaining lost fat. On average, participants who discontinued tirzepatide regained around 13 kilograms within a year. Those on the reduced 5 mg dose regained about 6 kilograms, while people continuing the full dose maintained nearly all their progress and even lost a little more weight on average.

The findings expose what some doctors are beginning to call the uncomfortable “subscription reality” of modern obesity treatment. The medicine may work remarkably well, but for many patients, staying healthy could mean staying on treatment for years — possibly for life.

Researchers reported that 67% of participants switched to placebo eventually needed “rescue treatment” after regaining excessive weight. In contrast, only 8% of those staying on the full dose required intervention.

“Our results demonstrated that the majority of the participants continuing tirzepatide maintained most of the bodyweight reduction initially achieved,” the authors said. “Discontinuing effective treatment in people living with obesity resulted in reversal of therapeutic benefit and caused significant weight regain.”

The study also found that continuing treatment helped preserve improvements in waist circumference, cholesterol, blood pressure and quality of life. Most side effects involved mild-to-moderate stomach problems, particularly during dose increases.

The findings echo earlier obesity research from Europe and the United States showing that the body often reacts to rapid weight loss as if it is under threat, slowing metabolism and increasing hunger hormones in an attempt to recover lost weight. Scientists say this biological defence system may explain why so many people struggle with repeated cycles of dieting and regain.

For patients who believed the new generation of “skinny shots” had finally ended the era of yo-yo dieting, the new evidence delivers a sobering message. The battle against obesity may not end when the weight disappears from the weighing scale. For many, it may only be entering its long maintenance phase.